checkAd

     332  0 Kommentare MYOS Corporation to Host Conference Call to Discuss Quarterly Update and Management Highlights

    CEDAR KNOLLS, NJ--(Marketwired - Mar 27, 2015) -  MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it plans to file its Annual Report on Form10-K ("Form 10-K") with the Securities and Exchange Commission after the market closes on Friday, March 27th, 2015. The Form 10-K may be accessed via the SEC filings page of the Investor Relations section of the Company's corporate web site at www.myoscorp.com.

    MYOS' management team will host a conference call and webcast on Monday March 30th, 2015 at 10:00 a.m. ET to provide a quarterly update and management highlights. Interested parties may access this conference call by dialing 877-407-7186 (U.S./Canada) or 201-689-8052 (International).

    The webcast may be accessed via the News and Events page of the Investor Relations section of the MYOS corporate web site at www.myoscorp.com and will be archived for 7 days. Webcast participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.

    About MYOS Corporation
    MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin®, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com

    Seite 1 von 3


    Verfasst von Marketwired
    MYOS Corporation to Host Conference Call to Discuss Quarterly Update and Management Highlights CEDAR KNOLLS, NJ--(Marketwired - Mar 27, 2015) -  MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve …